Live Breaking News & Updates on Patients With Poor Response

Stay updated with breaking news from Patients with poor response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Intercept Pharmaceuticals : EASL 2023 Podium Presentation of OCA-bezafibrate Combination Planned Interim Analysis

Results from a planned interim analysis of a randomized, double- blind, active-controlled trial evaluating the effects of obeticholic acid and bezafibrate on serum biomarkers in primary biliary cholangitis

. ....

Czech Republic , United States , Region Flamande , Antonio Civitarese , Frederik Nevens , Lynda Szczech , Alexandre Louvet , Vaclav Hejda , Cheng Zou , University Hospital In Pilsen , University Hospital Of Lille , Intercept Pharmaceuticals Inc , University Hospital Ku Leuven , Primary Biliary Cholangitis , Data Showed Promise With , Obeticholic Acid , Patients With Poor Response , Alkaline Phosphatases , Free Survival Demonstrated , External Controls , Range Exploration , Fixed Dose Combination ,